Review of immune tolerance induction in hemophilia A

At first sight the bleeding disorder hemophilia A seems to have little in common with immune disorders, but immunology research intersects with other disciplines including hematology.Nowadays, the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A. This antibody response renders FVIII replacement therapy ineffective, thereby increasing the risk for uncontrollable bleeding and morbidity, decreasing quality of life and increasing healthcare costs.

Source: Blood Reviews - February 15, 2018 Category: Hematology Authors: S.J. Schep, R.E.G. Schutgens, K. Fischer, M.L. Boes Tags: Review Source Type: research